ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Tyrosine kinase inhibitors (TKIs) targeting the ABL and BCR::ABL1 adenosine triphosphate (ATP) binding sites have significantly extended the lives of patients with chronic myeloid leukemia (CML) [1–5].